Literature DB >> 11306584

A CD45 polymorphism associated with multiple sclerosis disrupts an exonic splicing silencer.

K W Lynch1, A Weiss.   

Abstract

Previous studies have identified a single nucleotide polymorphism that significantly increases the splicing of variable exon 4 in transcripts of the human protein-tyrosine phosphatase CD45. Strikingly, the presence of this polymorphism correlates with susceptibility to the autoimmune disease multiple sclerosis. In this study we investigated the mechanism by which the polymorphism enhances splicing of CD45 exon 4. We found that at least four distinct splicing regulatory elements exist within exon 4 and that the strongest of these elements is an exonic splicing silencer (designated ESS1), which is disrupted by the polymorphism. We show that ESS1 normally functions to repress the weak 5' splice site (ss) of CD45 exon 4. The ESS1 sequence also suppresses the splicing of a heterologous 5'ss and associates with a specific complex in nuclear extracts. We further demonstrate that ESS1 is juxtaposed to a purine-rich enhancer sequence that activates the use of the 5'ss of exon 4. Thus, proper functioning of the immune system is dependent on a complex interplay of regulatory activities that mediate the appropriate splicing of CD45 exon 4.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11306584     DOI: 10.1074/jbc.M102175200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  PTPRC (CD45) C77G mutation does not contribute to multiple sclerosis susceptibility in Sardinian patients.

Authors:  Eleonora Cocco; Maria Rita Murru; Cristina Melis; Lucia Schirru; Elisabetta Solla; Marina Lai; Marcella Rolesu; Maria Giovanna Marrosu
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

Review 2.  Regulation of alternative RNA splicing by exon definition and exon sequences in viral and mammalian gene expression.

Authors:  Zhi-Ming Zheng
Journal:  J Biomed Sci       Date:  2004 May-Jun       Impact factor: 8.410

3.  Overexpression of CD45RA isoforms in carriers of the C77G mutation leads to hyporeactivity of CD4+CD25highFoxp3+ regulatory T cells.

Authors:  C Pokoyski; T Lienen; S Rother; E Schock; A Plege-Fleck; R Geffers; R Schwinzer
Journal:  Genes Immun       Date:  2015-09-10       Impact factor: 2.676

4.  Single-nucleotide polymorphisms in NAGNAG acceptors are highly predictive for variations of alternative splicing.

Authors:  Michael Hiller; Klaus Huse; Karol Szafranski; Niels Jahn; Jochen Hampe; Stefan Schreiber; Rolf Backofen; Matthias Platzer
Journal:  Am J Hum Genet       Date:  2005-12-22       Impact factor: 11.025

5.  Transcriptome-wide RNA interaction profiling reveals physical and functional targets of hnRNP L in human T cells.

Authors:  Ganesh Shankarling; Brian S Cole; Michael J Mallory; Kristen W Lynch
Journal:  Mol Cell Biol       Date:  2013-10-28       Impact factor: 4.272

Review 6.  Regulatory polymorphisms underlying complex disease traits.

Authors:  Julian C Knight
Journal:  J Mol Med (Berl)       Date:  2004-12-09       Impact factor: 4.599

7.  Receptor type protein tyrosine phosphatases (RPTPs) - roles in signal transduction and human disease.

Authors:  Yiru Xu; Gary J Fisher
Journal:  J Cell Commun Signal       Date:  2012-08-01       Impact factor: 5.782

8.  HnRNP L represses exon splicing via a regulated exonic splicing silencer.

Authors:  Caryn R Rothrock; Amy E House; Kristen W Lynch
Journal:  EMBO J       Date:  2005-07-07       Impact factor: 11.598

9.  G Run-mediated recognition of proteolipid protein and DM20 5' splice sites by U1 small nuclear RNA is regulated by context and proximity to the splice site.

Authors:  Erming Wang; William F Mueller; Klemens J Hertel; Franca Cambi
Journal:  J Biol Chem       Date:  2010-12-02       Impact factor: 5.157

10.  SRRM2, a potential blood biomarker revealing high alternative splicing in Parkinson's disease.

Authors:  Lina A Shehadeh; Kristine Yu; Liyong Wang; Alexandra Guevara; Carlos Singer; Jeffery Vance; Spyridon Papapetropoulos
Journal:  PLoS One       Date:  2010-02-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.